Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Luigi Meneghini

Endocrinology, Diabetes & Metabolism Dallas, TX Medical Doctor

NPI 1245295831 CMS profile 101311

5323 Harry Hines Blvd, Dallas, TX 75390

Open in the dashboard

General payments

$136,228

33 records reported · program years 2019–2020

Research payments

$28,121

Paid to them · 31 records reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Luigi Meneghini of Dallas, TX is reported in the CMS Open Payments database as having received $136,228 across 33 general payments and $28,121 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $36,832 9
2020 Research $9,503 13
2019 General $99,396 24
2019 Research $18,618 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luigi Meneghini
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Luigi Meneghini were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Luigi Meneghini Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $99,396 $494 $123–$2,253 $163
2020 $36,832 $335 $85–$1,841 $114
2021 $0 $398 $88–$1,981 $132
2022 $0 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Novo Nordisk Inc $78,610 16 payments
  2. Sanofi-Aventis U.S. LLC $57,617 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Consulting Fee $67,486 8 payments
  2. Travel and Lodging $44,600 15 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,505 3 payments
  4. Food and Beverage $637 7 payments
Products named General payments · program years 2019–2020
  1. TOUJEO Diabetes $27,061 8 payments
  2. Xultophy 100/3.6 $25,497 5 payments
  3. TOUJEO Endocrinology $25,290 7 payments
  4. SOLIQUA 100/33 Diabetes $21,998 5 payments
  5. SOLIQUA 100/33 Endocrinology $4,487 1 payment
  6. NO PRODUCT DISCUSSED $780 1 payment
  7. NovoLog $83 1 payment
  8. Levemir $83 1 payment
  9. NovoLog Mix 70/30 $83 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2020
  1. Sanofi-Aventis U.S. LLC $28,121 31 payments

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record